Prospective Analysis of Loteprednol Etabonate Ophthalmic Suspension 0.25% for Prevention of Immunologic Rejection After Descemet Membrane Endothelial Keratoplasty
Latest Information Update: 08 Sep 2023
At a glance
- Drugs Loteprednol etabonate (Primary)
- Indications Keratoplasty rejection
- Focus Adverse reactions; Therapeutic Use
- 05 Sep 2023 Status changed from active, no longer recruiting to completed.
- 02 Aug 2023 According to a Kala Pharamceuticals media release, Kala Pharamceuticals has changed its name to KALA BIO.
- 06 Jan 2023 Planned End Date changed from 1 Feb 2023 to 1 Aug 2023.